-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Refractory Multiple Myeloma Drug Details: NKTR-255 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-400 in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-400 in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-400 in Uterine Cancer Drug Details: ABBV-400 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Neuroendocrine Tumors
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HEC-68498 in Neuroendocrine Tumors Drug Details: HEC-68498 is under development for the treatment of idiopathic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-68498 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-68498 in Colorectal Cancer Drug Details:HEC-68498 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-68498 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-68498 in Solid Tumor Drug Details:HEC-68498 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegcetacoplan in Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegcetacoplan in Glomerulonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegcetacoplan in Glomerulonephritis Drug Details: Pegcetacoplan (Empaveli, Aspaveli) is a synthetic peptide acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Magrolimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Magrolimab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Magrolimab in Non-Small Cell Lung Cancer Drug Details: Magrolimab...
-
Company Insights
Innovation and Patenting activity of Yichang Hec Changjiang Pharmaceutical Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Yichang Hec Changjiang Pharmaceutical Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Company Insights
Innovation and Patenting activity of Guangdong HEC Technology Holding Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Guangdong HEC Technology Holding Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-88473 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-88473 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-88473 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:HEC-88473 is under development for the treatment...